骨髓增生异常综合征输血治疗相关难题及解决策略  

Problems and strategies of blood transfusion therapy for myelodysplastic syndromes

作　　者：徐文皓[1] 肖超[2] XU Wenhao;XIAO Chao(Department of Transfusion;Department of Hematology,Shanghai Jiaotong University Affliated Shanghai Sixth People Hospital,Shanghai 200233,China)

机构地区：[1]上海交通大学附属第六人民医院输血科,上海200233 [2]上海交通大学附属第六人民医院血液科,上海200233

出　　处：《中国输血杂志》2020年第4期417-420,共4页Chinese Journal of Blood Transfusion

摘　　要：骨髓增生异常综合征(myelodysplastic syndromes,MDS)是一组起源于造血干细胞异质性髓系克隆性疾病。多数患者需要长期反复输血,这不仅导致铁过载,还会引起患者同种和/或自身免疫功能紊乱,免疫血液学检查结果显示阳性从而给输血工作带来挑战。本综述介绍近几年来国内外对MDS输血替代治疗的药物选择,患者免疫血液学常见疑难问题及其产生原因,有助于MDS患者减少输血依赖及长期输血引起的铁过载等不良反应,以期对MDS患者相关免疫血液学疑难问题及其背后的病理逻辑有所启示。Myelodysplastic syndromes(myelodysplastic syndromes,MDS)are a group of bone marrow disorders characterized by abnormal development of one or more heterogeneous myeloid hematopoietic cell lines that result in various cytopenias.Most patients need long-term repeated transfusion,which not only leads to iron overload,but also causes auto-and/or alloimmune dysfunction.Their immuno-hematological tests often show positive results,which bring challenges to transfusion testing.This review introduced drug choice for transfusion alternative therapy for MDS patients at home and abroad in recent years,also described the common immuno-hematological problems and their causes.It may help MDS patients reduce blood transfusion dependence and iron overload caused by long-term transfusion.At the same time,it may shed some enlightenment to the deeper immuno-hematological and pathological logic.

关 键 词：骨髓增生异常综合征 免疫血液学 输血 

分 类 号：R457.1[医药卫生—治疗学] R551.3[医药卫生—临床医学]